The E3 Ubiquitin Ligase Ro52 Negatively Regulates IFN-β Production Post-Pathogen Recognition by Polyubiquitin-Mediated Degradation of IRF3

Rowan Higgs, Joan Ní Gabhann, Nadia Ben Larbi, Eamon P. Breen, Katherine A. Fitzgerald and Caroline A. Jefferies

_J Immunol_ 2008; 181:1780-1786; doi: 10.4049/jimmunol.181.3.1780
http://www.jimmunol.org/content/181/3/1780

**Why The _JI_?**
- **Rapid Reviews! 30 days** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Speedy Publication!** 4 weeks from acceptance to publication

*average

**References**
This article cites 42 articles, 17 of which you can access for free at: http://www.jimmunol.org/content/181/3/1780.full#ref-list-1

**Subscription**
Information about subscribing to _The Journal of Immunology_ is online at: http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
The E3 Ubiquitin Ligase Ro52 Negatively Regulates IFN-β Production Post-Pathogen Recognition by Polyubiquitin-Mediated Degradation of IRF3

Rowan Higgs,* Joan Ní Gabhann,* Nadia Ben Larbi,* Eamon P. Breen,* Katherine A. Fitzgerald,† and Caroline A. Jefferies2,*

Induction of type I IFNs is a fundamental cellular response to both viral and bacterial infection. The role of the transcription factor IRF3 is well established in driving this process. However, equally as important are cellular mechanisms for turning off type I IFN production to limit this response. In this respect, IRF3 has previously been shown to be targeted for ubiquitin-mediated degradation postviral detection to turn off the IFN-β response. In this study, we provide evidence that the E3 ligase Ro52 (TRIM21) targets IRF3 for degradation post-pathogen recognition receptor activation. We demonstrate that Ro52 interacts with IRF3 via its C-terminal SPRY domain, resulting in the polyubiquitination and proteasomal degradation of the transcription factor. Ro52-mediated IRF3 degradation significantly inhibits IFN-β promoter activity, an effect that is reversed in the presence of the proteasomal inhibitor MG132. Specific targeting of Ro52 using short hairpin RNA rescues IRF3 degradation following polyI:C-stimulation of HEK293T cells, with a subsequent increase in IFN-β production. Additionally, shRNA targeting of murine Ro52 enhances the production of the IRF3-dependent chemokine RANTES following Sendai virus infection of murine fibroblasts. Collectively, this demonstrates a novel role for Ro52 in turning off and thus limiting IRF3-dependent type I IFN production by targeting the transcription factor for polyubiquitination and subsequent proteasomal degradation. The Journal of Immunology, 2008, 181: 1780–1786.

Central to innate immune responses following viral and bacterial infection is the production of type I IFNs (IFN-α and -β) and the establishment of an antiviral or antibacterial state (1–3). Pathogen recognition receptors (PRRs) (3, such as the transmembrane TLRs or the cytosolic PRRs (RIG-I, MDA-5), respond to viral or bacterial infection and activate the regulatory networks that coordinate the induction of type I IFN genes. A family of transcription factors, the IFN regulatory factors (IRFs), has gained much attention in this respect, as IRF3 and IRF7 have been demonstrated to be essential for type I IFN gene induction in response to pathogen recognition (4–6). However, overproduction of type I IFNs results in adverse pathogenic effects characteristic of many autoimmune disorders, such as systemic lupus erythematosus (SLE) (7). Thus, understanding the mechanisms that limit or down-regulate type I IFN production downstream of pathogen recognition is critical to protecting against such harmful effects.

One mechanism by which IFN-β production is turned off post-PRR stimulation is via polyubiquitination and subsequent degradation of the transcription factor IRF3 (8–10). IRF3 is a constitutively expressed member of the IRF family that regulates the primary induction of IFN-β in response to viral and bacterial infection downstream of TLR3, TLR4, and cytosolic PRRs (4, 5, 11, 12). Both TLR3 and TLR4 induce type I IFN production in a similar fashion, through the recruitment and activation of the TIR domain containing adaptor inducing IFN-β (TRIF) (3–5, 11). This leads to the phosphorylation of IRF3 by IKKε and TBK1, followed by IRF3 nuclear translocation and induction of IFN-β transcription (13–15). IRF3 is also central to RIG-I and MDA-5 responses, which also involve IKKε and TBK1. The central role of IRF3 in mediating type I IFN induction in response to TLR3, TLR4, and intracellular PRRs would suggest that targeting it for ubiquitin-mediated degradation poststimulation is a very efficient way of shutting off and limiting the type I IFN response. Early work supporting this demonstrated that the proteasomal inhibitor MG132 inhibited IRF3 degradation in response to viral infection (8). More recently, the peptide-prolyl isomerase Pin1 was shown to interact with IRF3 following polyinosinic:polycytidylic acid (polyI:C) stimulation of 293T cells and promote polyubiquitination and proteasomal degradation of the transcription factor (9). Additionally, the involvement of a cullin-based ubiquitin ligase in Sendai virus-induced IRF3 degradation has been reported (10). Importantly, the E3 ligase responsible for targeting IRF3 has not yet been identified.

Ubiquitin-mediated proteasomal degradation regulates many biological events including cell cycle control, signal transduction, DNA repair, and apoptosis (16, 17). Ubiquitination involves three enzymes: an E1 ubiquitin-activating enzyme, an E2 ubiquitin-conjugating enzyme, and an E3 ubiquitin-ligase.

*Address correspondence and reprint requests to Dr. Caroline Jeffries, Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland; and †Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605.

Received for publication February 15, 2008. Accepted for publication May 23, 2008.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was funded by Science Foundation Ireland, the Health Research Board, and by National Institute of Allergy and Infectious Diseases, National Institutes of Health (AI067497 to K.A.F.).

2 Address correspondence and reprint requests to Dr. Caroline Jeffries, Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 123 St. Stephen’s Green, Dublin 2, Ireland. E-mail address: cjefferies@rcsi.ie

3 Abbreviations used in this paper: PRR, pathogen recognition receptor; IRF, interferon regulatory factor; SLE, systemic lupus erythematosus; TRIF, TIR domain containing adaptor inducing IFN-β; HEK, human embryonic kidney; HA, hemagglutinin; PRD, positive regulatory domain; polyI:C, polyinosinic:polycytidylic acid; shRNA, short hairpin RNA.
enzyme, and an E3 ubiquitin ligase. It is the E3 ligase that provides the specificity in the ubiquitin process as it recruits both the E2 ubiquitin complex and the target protein, often resulting in polyubiquitination and proteasomal degradation by the 26S proteasome (18). Members of the TRIM family are single-protein E3 ligases that have multiple roles in cell biology (19) and their substrate specificity is determined by the C-terminal SPRY domain (20, 21). Ro52 (TRIM21) was first described as a target for autoantibody production in SLE and Sjögren’s syndrome (22–24). Interestingly, TRIM family members, such as TRIM5α and TRIM25, have been shown to play important roles in antiviral defenses (19, 25, 26). Recent work identifying IRF8 as a direct substrate for Ro52 (27) suggests a role for Ro52 in immune responses. Indeed, recent work identifying IRF8 as a direct substrate for Ro52 shown to play important roles in antiviral defenses (19, 25, 26).

In this study, we show that IRF3 is specifically targeted by Ro52 for ubiquitin-mediated degradation to negatively regulate the IFN-β promoter downstream of LPS and polyIC stimulation and Sendai virus infection. In addition, we demonstrate that inhibiting Ro52 expression with short hairpin RNA (shRNA) results in enhanced TLR3-driven IFN-β production and Sendai virus-stimulated RANTES production. Taken together, our results demonstrate a novel role for Ro52 as a negative regulator of type I IFN induction downstream of pathogen recognition.

Materials and Methods

Cell culture

THP1 cells were cultured in RPMI 1640 supplemented with 10% FCS and 10 μg/ml gentamicin. Human embryonic kidney (HEK) 293 cells stably transfected with TLR3 (TLR3–293) or TLR4 (TLR4/MD2–293), HEK293T cells, HeLa cells, and NIH 3T3 cells were cultured in DMEM supplemented with 10% FCS and 10 μg/ml gentamicin. TLR3–293 and TLR4–293 cells were cultured in the presence of 500 μg/ml G418 (Sigma-Aldrich).

Plasmids and reagents

Flag-tagged pCMV-IRF3, Flag-tagged pCMV-IRF7, pEF-Bos-TRIF-Flag, and the IFN-β promoter constructs were from Dr. Kate Fitzgerald (University of Massachusetts Medical School, Worcester, MA). Xpress-tagged Ro52, Xpress-tagged Ro52ΔExon1, and Xpress-tagged Ro52ΔExon6 were gifts from Dr. David Rhodes (Cambridge Institute for Medical Research, Cambridge, U.K.) and hemagglutinin (HA)-ubiquitin from Dr. Andrew Bowie (School of Biochemistry with Immunology, Trinity College Dublin, Ireland). The NF-κB-luciferase plasmid was a gift from Dr. R. Hofmeister (Universitat Regensburg, Regensburg, Germany). Primary Abs used were anti-HA, anti-IRF3 (Santa Cruz Biotechnologies), anti-Flag (Sigma-Aldrich), anti-Xpress (Invitrogen Life Technologies), anti-polyubiquitin FK1 (BIOMOL), and anti-β-actin (Abcam). Polyclonal Abs against Ro52 that were used in immunoprecipitation experiments were made by Sigma-Genosys and anti-Ro52 Abs used in Western blots were purchased from BioReagents, Cambridge, U.K.

Luciferase reporter gene assays

HEK293T, TLR3–293, and TLR4/MD2–293 cells were transiently transfected for 18 h with 50 ng of the indicated reporter constructs and increasing amounts of a Ro52 construct (10, 50, and 100 ng). HEK293T cells were also cotransfected with either a TRIF or IRF3 construct (50 ng). All transfections were performed using Metafectene (Biontex) according to the manufacturer’s recommendations. Following transfection, TLR3–293 and TLR4/MD2–293 cells were either untreated or stimulated with polyIC (20 μg/ml) or LPS (1 μg/ml) for 6 h. Luciferase activity was standardized by Renilla luciferase plasmid activity to normalize for transfection efficiency.

Western blot and immunoprecipitation

Immunoblots were performed as described previously (28). Cells were lysed on ice in 1× radioimmune precipitation lysis buffer (1× PBS, 1% Nonidet P-40, 0.5% Na-deoxycholate, 0.1% SDS, 1 mM KF, 1 mM Na3VO4, 10 μg/ml leupeptin, and 1 mM PMSF) followed by immunoprecipitation with either anti-HA agarose, or anti-Flag or anti-Ro52 bound to protein-G Sepharose beads. For peptide pulldowns, lysates were incubated with 1 μg His-Ro52 bound to Ni2+–agarose beads (Qiagen). Immunoprecipitates were analyzed by Western blot. Each blot is representative of two to three independent experiments.

Realtime PCR

RNA was extracted from cell cultures using TRIzol (Invitrogen Life Technologies) and reverse transcribed to cDNA using Omniscript reverse transcriptase (Qiagen) according to the manufacturer’s recommendations. Quantitative realtime PCR was performed using SYBR Green Taq Ready-Mix (Sigma-Aldrich) on an Applied Biosystems 7500 realtime PCR machine at an annealing temperature of 56°C. Realtime PCR data was analyzed using the 2−△△Ct method (29).

RNA interference

A shRNA sequence targeting human Ro52 (30) was cloned into the pRNA-H1.1/neom construct and used in parallel. The 293T and TLR3–293 fibroblast cells were transfected with 1 μg of Ro52 shRNA or 1 μg of scrambled control shRNA, using Metafectene according to the manufacturer’s recommendations. Following 24 h of transfection, cells were treated with polyIC (25 μg/ml) for the indicated times. IFN-β and IRF-3 mRNA levels were measured.
293T cells were transfected with 50 ng full-length IFN-β/H9252 promoter following LPS stimulation, but is not involved in regulating 100 multiplicities of infection (MOI) and promoter activity was measured. Cells were cotransfected with 100 ng Ro52 or EV control and 18-h posttransfection supernatants were collected from NIH 3T3 cells and RANTES production was measured by ELISA (R&D Systems) according to the manufacturer's recommendations.

Results

Ro52 acts downstream of TLR4, TLR3, and RIG-I to negatively regulate activation of the IFN-β promoter

TRIM family members have been shown to be important in mediating antiviral immunity (19, 25, 26). Given this and the putative role of Ro52 in regulating immune function (27, 30), we investigated the effect of Ro52 expression on TLR-driven NF-κB- and IFN-β-reporter gene activity. Although transient transfection of TLR4/MD2–293 cells with increasing concentrations of Ro52 had no effect on the activation of the NF-κB promoter in response to LPS stimulation (Fig. 1A), Ro52 dose-dependently inhibited TLR4-driven IFN-β-reporter gene activity (Fig. 1B). This result suggests that Ro52 acts by negatively regulating the IFN-β promoter following LPS stimulation, but is not involved in regulating NF-κB. Ro52 inhibition of the IFN-β promoter was also observed following poly(I:C) stimulation of similarly transfected TLR3–293 cells (Fig. 1C).

IFN-β has four regulatory cis-elements in its enhancer region: positive regulatory domains (PRDs) I-IV (Fig. 1D). NF-κB and ATF-c-Jun bind to PRD II and IV, respectively, while IRF3/7 bind overlapping PRD I and III elements. Looking at the effect of Ro52 on TRIF-driven IFN-β promoter activity in 293T cells, we found that while Ro52 dose-dependently inhibited the full-length promoter (Fig. 1E), its effects were localized to PRD I/III (Fig. 1F) and not PRD II (data not shown), suggesting that Ro52 specifically regulates IRF3 activation. Thus, we assessed if Ro52 could inhibit IRF3-driven IFN-β promoter activity directly using the constructs shown in Fig. 2A. Increasing amounts of Ro52 significantly inhibited the ability of IRF3 to induce the IFN-β promoter in a dose-dependent manner (Fig. 2B). Furthermore, plasmids encoding Ro52 mutants lacking either the N-terminal RING-finger domain or C-terminal SPRY domain were unable to inhibit IRF3-driven IFN-β promoter activity (Fig. 2, C and D, respectively), indicating that both domains are functionally important for the negative effect of Ro52.
As the intracellular PRR RIG-I, which recognizes Sendai virus, also signals through IRF3, we examined the effect of Ro52 on Sendai virus infection of 293T cells. Ro52 potently inhibited IFN-β promoter activation following infection of cells with Sendai virus, confirming that RIG-I-regulated activation of IRF3 is also targeted by Ro52 (Fig. 2E).

**Ro52 associates with IRF3**

Our studies on the effects of Ro52 on the IFN-β promoter strongly indicated that the target for Ro52 was IRF3. To address this hypothesis, we investigated the possibility that Ro52 and IRF3 interact. Accordingly, 293T cells were transfected with a construct expressing Flag-tagged IRF3. The ability of overexpressed IRF3 to interact with Ro52 was assessed in a pull-down experiment using recombinant His-tagged Ro52. Fig. 3A demonstrates that Flag-IRF3 strongly associates with His-Ro52, suggesting that IRF3 may be an endogenous substrate for Ro52. Interestingly, Ro52 also associates with IRF7, which is important for the secondary type I IFN response following LPS stimulation.

To determine which domain of Ro52 is involved in the association with IRF3, plasmids expressing either full-length Ro52 or Ro52 lacking either the N-terminal RING-finger domain or C-terminal SPRY domain were used in coexpression studies with Flag-IRF3. As expected, full-length Ro52 interacted with Flag-IRF3 as shown by the increased intensity of the observed band compared with empty vector control (Fig. 3B, upper panel, lane 3). However, as Ro52 consistently comigrated with the H-chain of the IgG molecule, we repeated the separation using 50% sample volume to make the association more distinct (Fig. 3B, lower panel). Importantly, while Flag-IRF3 was able to interact with Ro52 lacking the RING domain (Ro52ΔExon1), no association was observed between Flag-IRF3 and Ro52 lacking the C-terminal SPRY domain (Ro52ΔExon6) (Fig. 3B). This result indicates that the C-terminal SPRY domain of Ro52 is crucial for its interaction with IRF3.

We next looked at the ability of Ro52 and IRF3 to interact endogenously. HeLa cells were stimulated with polyI:C at specific time points and cell lysates were incubated with anti-Ro52 Ab coupled to Sepharose beads in an immunoprecipitation experiment. Importantly, the endogenous association between Ro52 and IRF3 was stimulation dependent, with no apparent association under resting conditions, whereas a substantial increase in the association between the two proteins was observed at 2–4 h poststimulation (Fig. 3C). This was accompanied by an increase in higher migrating m.w. bands in the IRF3 immunoblot, indicative of increased polyubiquitination. Furthermore, accompanying the association between the two proteins, a decrease in total IRF3 levels was observed at 4–8 h poststimulation. This suggests that polyI:C-induced degradation of IRF3 may be Ro52-dependent.

**Ro52 promotes the ubiquitination and degradation of IRF3**

In our experimental system, IRF3 ubiquitination was observed following PRR stimulation, consistent with previous reports (data not shown). Studies have shown that Ro52 functions as an E3 ligase (23, 31, 32). Having first confirmed that Ro52 autoubiquitinates and thus has E3 ligase activity (data not shown), we next examined if the observed association between Ro52 and IRF3 was responsible for the observed ubiquitination of IRF3. In lysates from 293T cells, the presence of Xpress-Ro52 and HA-ubiquitin increased the polyubiquitination of Flag-IRF3 compared with HA-ubiquitin alone, as observed by the presence of multiple high molecular
mass bands (Fig. 4A). To confirm the ability of Ro52 to ubiquitinate IRF3, HA-ubiquitinated proteins were immunoprecipitated from 293T cells that had been transfected with HA-ubiquitin and Flag-IRF3 in the presence and absence of Ro52. As seen in Fig. 4B, the presence of Ro52 markedly increased the polyubiquitination of IRF3. Total HA-ubiquitin modification was also examined and found to be similar in all lanes in which HA-ubiquitin was expressed, indicating that the increased IRF3 ubiquitination observed in the presence of Ro52 is not due to an increase in total ubiquitin. Taken together, these results indicate that Ro52 targets IRF3 for polyubiquitination.

One consequence of polyubiquitination of proteins is subsequent proteasomal-mediated degradation. Consistent with a role for Ro52-mediated polyubiquitination of IRF3 in promoting its degradation, we observed that IRF3 levels were reduced in 293T cells coexpressing Flag-IRF3 and Xpress-Ro52, (Fig. 4C, panel 1, lane 4). Furthermore, this effect was substantially increased when HA-ubiquitin was coexpressed (Fig. 4C, panel 1, lane 5). Pretreatment of cells with the proteasomal inhibitor MG132 completely rescued IRF3 degradation, confirming that the observed IRF3 degradation was proteasome dependent (Fig. 4C, panel 1, lanes 9–10). The ability of MG132 to inhibit proteasomal degradation is shown by the accumulation of total polyubiquitinated proteins (Fig. 4C, panel 4, lanes 6–10).

We next determined if Ro52-mediated IRF3 degradation had a direct effect on IFN-β promoter activity. Ro52 dose-dependently inhibited the IFN-β promoter when driven by IRF3 in 293T cells (Fig. 4D). However, inhibition of the proteasome with MG132 resulted in a significant rescue of IFN-β promoter activity, suggesting that Ro52-induced IRF3-degradation is responsible for inhibition of the IFN-β promoter. This corresponded with a dose-dependent decrease in the levels of IRF3 in the cells transfected with Ro52, which was rescued following MG132 treatment (data not shown).

**Ro52 functions as a negative regulator of IFN-β signaling by degrading IRF3**

To determine the functional relevance of Ro52-mediated degradation of IRF3 and its corresponding effects on the IFN-β promoter, we targeted the expression of Ro52 in 293T cells using shRNA constructs directed against human Ro52. As expected, polyI:C stimulation of cells treated with a nontarget scrambled shRNA resulted in IRF3 degradation, an effect that could be seen by 8 h post-TLR3 stimulation. In contrast, knockdown of Ro52 using shRNA resulted in an accumulation of IRF3, consistent with a role for Ro52 as a negative regulator of IRF3 protein levels post-PRR stimulation (Fig. 5A). In addition, IRF3 degradation in response to PRR stimulation was rescued in Ro52-depleted NIH 3T3 cells compared with control cells (data not shown). We next measured the effects of Ro52 knockdown on IFN-β mRNA levels using real-time PCR. While basal levels of the IFN-β gene were comparable between cells treated with Ro52 shRNA or scrambled shRNA control (data not shown), treatment of cells with polyI:C for 48 h resulted in a 40-fold induction of the IFN-β gene in the presence of Ro52 shRNA compared with a 15-fold increase in gene induction in control cells (Fig. 5B). In contrast, there was no difference in IRF3 gene induction, suggesting that the effect of Ro52 observed in Fig. 5A is specific to IRF3 protein (data not shown). Additional experiments confirmed these findings, using NIH 3T3 murine fibroblast cell lines stably transfected with either scrambled shRNA or Ro52 shRNA (Fig. 5C). Consistent with previous findings in 293T cells, following Sendai-virus infection, induction of the IFN-β-stimulated chemokine RANTES was significantly increased in Ro52-depleted cells compared with control cells (Fig. 5C).

Collectively, these results indicate that loss of Ro52 in the cells results in an accumulation of the transcription factor IRF3 and subsequently an enhanced production of IFN-β. This implicates Ro52 in targeting IRF3 protein to turn off and limit IFN-β production post-pathogen detection by PRRs.

**Discussion**

In this study, we have identified Ro52 as an E3 ligase that acts to limit IFN-β production downstream of pathogen recognition receptors, specifically TLR3, TLR4, and RIG-I. Our results demonstrate that Ro52 achieves these effects by polyubiquitinating the transcription factor IRF3, thus targeting it for proteasomal-mediated degradation. By degrading IRF3, Ro52 prevents excessive production of IFN-β in response to pathogen detection.
Negative regulation of antiviral pathways post-PRR activation via ubiquitination of key downstream components is an effective way to turn off and limit the production of type I IFNs. Indeed, targeted degradation of RIG-I by the E3 ligase RNF125 has recently been described and negatively regulates IFN-β production in response to infection of cells with Sendai virus (33). In addition, the anti-apoptotic protein A20 has been shown to be a potent inhibitor of RIG-I-mediated activation of both IRF3 and NF-κB, an effect that requires its E3 ligase activity, and not its deubiquitinating activity (34, 35). We investigated a possible role for the E3 ligase Ro52 as a negative regulator of TLR-dependent pathways. While Ro52 had no effect on TLR4-driven NF-κB-dependent reporter gene activity, subsequent results indicated that Ro52 negatively regulated pathways promoting IFN-β production in response to TLR stimulation. Further analysis indicated that its target lay downstream of TRIF, with IRF3, and not NF-κB, being a candidate target for Ro52. In addition, through the use of Ro52 mutants, we have shown that the N-terminal RING-finger domain is essential for the observed inhibition of IFN-β promoter activity, indicating that Ro52 may be acting as an E3 ligase in this pathway, targeting IRF3 for degradation.

Down-regulation of IRF3 activation by ubiquitin-mediated degradation is an efficient means to turn off IFN-β production, thus making IRF3 a prime target for viral immune evasion strategies (reviewed in Ref. 12, 36). In this context, bovine herpesvirus 1 infected cell protein 0 has been shown to act as an E3 ligase and promote IRF3 degradation in a proteasome-dependent manner, thus inhibiting the IFN-β promoter (37). Investigation into endogenous mechanisms targeting IRF3 to down-regulate type I IFN signaling downstream of pathogen detection has focused on the involvement of a cullin-based ubiquitin ligase in the polyubiquitination and subsequent degradation of IRF3, however the E3 ligase responsible has not been identified (10).

In this study, we have identified Ro52 as an endogenous E3 ligase responsible for regulating IRF3 levels. Ro52 was found to associate with IRF3 via the C-terminal domain SPRY domain of Ro52, thought to be involved in protein-protein interactions (20, 21). We demonstrate in this study that the observed association of Ro52 with IRF3 promotes the polyubiquitination and subsequent proteasomal-mediated degradation of IRF3. In addition, Ro52 dose-dependently inhibits IRF3-driven IFN-β promoter activity and this effect is significantly reversed in the presence of the proteasomal inhibitor MG132, suggesting that inhibition of the IFN-β promoter is a direct consequence of Ro52-mediated degradation of IRF3. Critically, we have demonstrated that the observed association between Ro52 and IRF3 in over-expression studies also occurs endogenously and that it is stimulation dependent. Our results show that Ro52 associates with IRF3 2–4 h post-polyLC-stimulation and that this is accompanied by a subsequent loss of IRF3 levels in the cells. Furthermore, targeting Ro52 with shRNA, and thus inhibiting Ro52-induced IRF3-degradation, results in enhanced TLR3-driven IFN-β production and Sendai virus-stimulated RANTES production, confirming our hypothesis that Ro52 negatively regulates IFN-β production post-PRR stimulation by targeting IRF3 for degradation.

As this manuscript was in preparation, Kong et al. (27) described a role for Ro52 in ubiquitinating the transcription factor IRF8, which positively regulates IL-12p40 production in murine macrophages. Like Kong et al., we identify a member of the IRF family, IRF3, as a target for Ro52. We also observed an interaction between Ro52 and IRF7, suggesting a global role for Ro52 in regulating the IRF family. Further work on the role of Ro52 in IRF7 signaling will be revealing as previous studies have shown enhanced IRF7 activity following ubiquitination by both TRAF6 and the EBV oncoprotein LMP1 (38, 39).

Collectively, our results demonstrate that the E3 ligase Ro52 targets IRF3 for polyubiquitination and proteasomal-mediated degradation. The overall function of this targeted degradation of IRF3 is to turn off or limit the production of IFN-β post-pathogen detection. In this context, our current focus is to determine how Ro52 is regulated post-PRR stimulation, specifically which E2 ligase is involved and if Ro52 is posttranslationally modified. Interestingly, Ro52 is best known for its ability to act as an autoantigen in SLE and Sjögren’s syndrome. Whether there is a possible link between increased levels of Ro52 autoantibodies in patients with SLE and Sjögren’s syndrome, and Ro52 function as a regulator of IFN-β production, remains to be seen. In addition, Ro52 polymorphisms have been described that are associated with SLE (40), and linkage analysis reports have indicated chromosome 11p15.5, containing the Ro52 locus, as a susceptibility region for SLE (41, 42). Consequently, given its role in regulating IFN-β production described in this study, it is possible that Ro52 activity may be compromised in these autoimmune disorders, thus contributing to the increased production of type I IFNs associated with disease pathogenesis. Therefore, our findings have important implications for our understanding of mechanisms that regulate both antiviral immunity and autoimmunity.

Acknowledgments
We thank Professor Jim Johnston and Kiva Brennan for helpful discussion and comments on the manuscript.

Disclosures
The authors have no financial conflict of interest.

References
24. Wahren-Herlenius, M., S Muller, and D. Isenberg. 1999. Analysis of B-cell
20. Rhodes, D. A., and J. Trowsdale. 2007. TRIM21 is a trimeric protein that binds
16. Ben-Neriah, Y. 2002. Regulatory functions of ubiquitination in the immune sys-
12. Ben-Neriah, Y. 2002. Regulatory functions of ubiquitination in the immune sys-
10. Rhodes, D. A., and J. Trowsdale. 2007. TRIM21 is a trimeric protein that binds
5. Nisole, S., J. P. Stoye, and A. Saib. 2005. TRIM family proteins: retroviral re-